Core Insights - The mulberry leaf extract industry in China is rapidly developing due to the increasing demand for natural plant extracts and the medicinal and health benefits of mulberry leaves [1][6][22] - China is one of the richest countries in mulberry resources, with a complete industrial chain extending from mulberry cultivation to high-value extracts [1][4] - The market size for mulberry leaf extract is projected to grow from 199.17 million yuan in 2024 to 217.65 million yuan in 2025, with an industry output value expected to reach 300.65 million yuan [1][6] Industry Definition and Classification - Mulberry leaves (Folium Mori) are the dried leaves of the mulberry plant, known for their medicinal properties, including clearing lung heat and improving vision [2] - The main functional components of mulberry leaf extract include polyphenols, flavonoids, alkaloids, and polysaccharides, which are associated with antioxidant capabilities [2][4] Current Development Status - The mulberry leaf extract industry has seen a steady increase in demand due to rising health awareness and preference for natural products, leading to market expansion [4][6] - The production capacity of mulberry leaf extract in China is expected to grow from 834 tons in 2024 to 892 tons in 2025, with production increasing from 563 tons to 598.4 tons [4][6] Industry Chain - The upstream of the mulberry leaf extract industry includes mulberry cultivation and extraction production equipment, with raw material costs accounting for over 90% of the total cost [8][10] - The downstream applications of mulberry leaf extract include pharmaceuticals, cosmetics, health products, and food and beverages [8] Industry Development History - The plant extraction industry in China has a long history, with significant advancements in extraction methods since the 1990s, leading to a golden development period in the 21st century [15] Competitive Landscape - The mulberry leaf extract industry exhibits a clear technological stratification, with leading companies using proprietary technologies to dominate the high-end market [17][19] - Major companies in the industry include Hunan Xier Natural Pharmaceutical Co., Ltd., Hunan Huakang Biotechnology Co., Ltd., and Guilin Rhine Biotechnology Co., Ltd. [17][19] Industry Development Trends - The demand for mulberry leaf extract is expected to grow as consumers increasingly seek natural and healthy products, particularly in the fields of medicine, food, and health supplements [22]

桂林莱茵生物科技股份有 限公司 证券代码：002166 证券简称：莱茵生 物 公告编号：2025-039 桂林莱茵生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到控股 股东、实际控制人秦本军先生的通知，获悉秦本军先生将其质押给国泰海通证券 股份有限公司（以下简称"国泰海通"）的股份办理了解除质押，具体事项如下： 一、本次解除质押的基本情况 桂林莱茵生物科技股份有限公司 持股份比例、占公司总股本比例以及对应融资余额如下表所示： 到期的质押股份累计 占所持股份 占公司总股本 对应融资余额 时段 数量（万股） 比例 比例 （万元） 未来半年内到期 16,663.44 61.40% 22.47% 22,307.6107 未来一年内到期 16,663.44 61.40% 22.47% 22,307.6107 利益的情形。 份不存在平仓风险或被强制平仓的情形。其股份质押事项不会导致公司实际控制 权发生变更，不会对公司生产经营和公司治理产生影响，且不存在重大资产重组 等业绩补偿义务。若出现平 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-039 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到控股 股东、实际控制人秦本军先生的通知，获悉秦本军先生将其质押给国泰海通证券 股份有限公司（以下简称"国泰海通"）的股份办理了解除质押，具体事项如下： 二、股东股份累计质押情况 截至公告披露日，上述股东所持质押股份情况如下： | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 合计占 | 占公司 | | | 未质押 | | | | | 持股 | 累计被质 | | | 已质押股 | 占已质 | 股份限 | 占未 | | 股东 | 持股数量 | | | 其所持 | 总股本 | 份限售和 | | | 质押 | | 名称 | （万股） | 比例 | 押股份数 | 股份比 | 比例 | | 押股份 | 售和冻 | | | | | （%） | 量（万股） | | | 冻结、标记 | | | 股份 ...

证券代码：002166 证券简称：莱茵生物 公告编号：2025-038 桂林莱茵生物科技股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外担保进展情况概述 （一）本次对外担保情况 近日，桂林莱茵生物科技股份有限公司（以下简称"公司"）控股子公司成 都华高生物制品有限公司（以下简称"华高生物"）向成都银行股份有限公司蒲 江支行申请了人民币1,000万元最高额融资额度，该债务由成都金控融资担保有 限公司（以下简称"成都金控担保"）提供连带责任保证担保，担保金额为1,000 万元人民币。公司与成都金控担保签订了《最高额保证反担保合同》，就公司控 股子公司华高生物向成都银行股份有限公司蒲江支行申请最高额融资事项，向成 都金控担保提供主债权本金最高额1,000万元的连带责任保证反担保。该笔担保 完成后，公司就控股子公司华高生物向成都银行股份有限公司蒲江支行申请的贷 款提供的连带责任保证反担保总额为1,500万元。 桂林莱茵生物科技股份有限公司 （二）对外担保审议情况 公司于2025年3月26日召开第七届董事会第四次 ...

Group 1 - The event organized by Dongfang Securities aimed to enhance investor protection and transparency of listed companies, aligning with the new "National Nine Articles" policy [1] - The event featured a visit to the Guilin production base of Lain Bio, showcasing its advanced technologies and digital management processes in the plant extraction industry [1] - Lain Bio's production line for enzyme-synthesized RebM2 is the first of its kind globally, offering significant advantages over traditional methods, including lower energy consumption and higher raw material utilization [1] Group 2 - The company expects to produce over 1,000 tons of enzyme-synthesized products annually, with an estimated annual output value exceeding 1 billion yuan [1] - During the investor communication session, Lain Bio's secretary emphasized the importance of ongoing dialogue between the company and its investors [3] - Investors expressed increased confidence in Lain Bio's development after witnessing its operations firsthand, highlighting the event's role in enhancing understanding of the plant extraction industry's technological and market potential [3]

Core Viewpoint - The company has announced its profit distribution plan for the fiscal year 2024, which includes a cash dividend of 1.00 yuan per 10 shares for all shareholders, totaling approximately 72.63 million yuan [3][4]. Group 1: Profit Distribution Plan - The profit distribution plan was approved at the shareholders' meeting held on April 18, 2025, and is based on a total share capital of 741,623,525 shares, excluding 15,275,701 shares held in the company's repurchase account and 14,100 shares subject to judicial freeze [3][4]. - The cash dividend of 1.00 yuan per 10 shares (before tax) will be distributed to shareholders, with a total cash distribution amounting to 72,633,372.40 yuan [3][4]. - The reference price for ex-dividend will be adjusted based on the closing price on the record date minus the cash dividend per share [4][6]. Group 2: Shareholder Rights and Exclusions - Shareholders holding shares in the repurchase account and those with shares subject to judicial freeze will not be entitled to participate in this profit distribution [5][6]. - The record date for the distribution is set for June 6, 2025, and the ex-dividend date is June 9, 2025 [5][6]. Group 3: Taxation and Dividend Payment - The cash dividends will be directly credited to shareholders' accounts through their custodial securities companies [5]. - Different tax rates will apply to various categories of shareholders, with specific provisions for foreign investors and domestic funds [4][6].

桂林莱茵生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、桂林莱茵生物科技股份有限公司（以下简称"公司"或"本公司"）于 2024 年 11 月 28 日召开 2024 年第二次临时股东会，会议审议通过了《关于回购 注销 2022 年限制性股票激励计划部分限制性股票的提案》，并于 2025 年 2 月 5 日完成了《2022 年限制性股票激励计划》中激励对象持有的已获授但尚未解除 限售的限制性股票共计 363,300 股的回购注销手续，剩余应被回购注销的 14,100 股限制性股票因激励对象个人原因被司法冻结，暂未办理完回购注销手续。该部 分尚未完成回购注销的 14,100 股股份不享有本次利润分配的权利。同时，公司 通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份数量为 15,275,701 股，该部分股份不享有股东会表决权、利润分配、公积金转增股本等 相关权利。 因此，公司 2024 年度利润分配方案为：以公司现有总股本 741,623,525 股扣 除公司回购专用证券账户中的 15,275,701 股及公司限 ...

Core Insights - The beer sector experienced a rise of 1.14%, ranking 7th among concept sectors, with 15 stocks increasing in value, led by Lehui International, Qingdao Beer, and Zhujiang Beer, which rose by 10.02%, 3.05%, and 3.05% respectively [1][2][3] - The sector saw a net inflow of 0.92 billion yuan, with 13 stocks receiving net inflows, and five stocks exceeding 10 million yuan in net inflow, with Lehui International leading at 392.99 million yuan [2][3] Sector Performance - The beer concept sector had a positive performance with notable gains from key players such as Lehui International, Qingdao Beer, and Chongqing Beer, while stocks like Jinzongzi and Zhuhai Zhongfu faced declines [1][2] - The top gainers in the beer sector included Lehui International with a 10.02% increase, followed by Qingdao Beer at 3.05% and Chongqing Beer at 2.64% [3][4] Fund Flow Analysis - Lehui International, *ST Lanhua, and Jinhui Wine had the highest net inflow ratios at 11.44%, 7.57%, and 6.64% respectively, indicating strong investor interest [3][4] - The main inflow of funds was concentrated in Lehui International, which attracted 392.99 million yuan, followed by Qingdao Beer and Chongqing Beer with inflows of 270.70 million yuan and 224.53 million yuan respectively [2][3]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [7] Core Viewpoints - The company is leveraging synthetic biology to enhance the production of plant extracts, addressing key technological challenges in scaling natural product production [1] - The dual technology strategy of "natural extraction + biosynthesis" has been elevated to a strategic goal, with significant progress in the biosynthesis of natural sweeteners and polysaccharides [2] - The company has achieved breakthroughs in natural sweeteners and functional polysaccharides, including the mass production capability of steviol glycosides and the full synthetic pathway for monk fruit sweetener [3][4] Summary by Sections Industry Overview - The plant extract industry in China entered a quality improvement phase in 2021, with technological innovations driving development [1] Company Developments - Since 2016, the company has collaborated with research institutions to develop biosynthesis technologies for natural sweeteners, resulting in the establishment of two R&D platforms [2] - The company has obtained 8 patents in synthetic biology and has a production capacity of over 1,000 tons annually, with an expected annual output value exceeding 1 billion yuan [2] Product Progress - The company has developed a high-value steviol glycoside, Reb M2, which is set to receive FDA GRAS certification by February 2025, allowing it to be marketed in the US [3] - The company is the first to achieve a fully synthetic pathway for monk fruit sweetener, addressing the limitations of natural sourcing [3] - A new functional polysaccharide, L-β-glucan, has been developed with various health benefits and is expected to receive FDA GRAS certification by 2025 [4] Financial Forecast & Investment Recommendations - The company has adjusted its revenue forecasts for 2025-2027 to 2.08 billion, 2.48 billion, and 2.99 billion yuan respectively, with net profits of 212.53 million, 288.09 million, and 395.93 million yuan [5] - The company is expected to maintain strong growth in the plant extraction and synthetic biology sectors, justifying the "Buy" rating [5]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [7]. Core Insights - The company is leveraging synthetic biology to enhance the production of plant extracts, addressing key technological challenges in scaling natural product production [1]. - The dual technology strategy of "natural extraction + biological synthesis" has been elevated to a strategic goal, with significant progress in the field of natural sweeteners and polysaccharides [2]. - The company has achieved breakthroughs in natural sweeteners, including the mass production capability of steviol glycosides and the full synthetic pathway for monk fruit sweetener [3][4]. Summary by Sections Section 1: Industry Development - The plant extract industry in China entered a quality improvement phase in 2021, with technological innovations driving growth and reducing dependency on raw materials [1]. Section 2: Company Strategy - Since 2016, the company has collaborated with research institutions to develop biological synthesis technologies for natural sweeteners, resulting in the establishment of two R&D platforms [2]. - The company has obtained 8 patents in synthetic biology and has a production capacity of over 1,000 tons annually, with an expected annual output value exceeding 1 billion yuan [2]. Section 3: Product Progress - The company has developed a high-value steviol glycoside, Reb M2, which is set to receive FDA GRAS certification by February 2025, allowing it to be marketed in the U.S. [3]. - The company is the first to successfully synthesize monk fruit sweetener, addressing the limitations of natural sourcing [3]. - A new functional polysaccharide, L-β-galactomannan, has been developed with various health benefits and is expected to receive FDA GRAS certification by 2025 [4]. - The company is actively researching ergothioneine, which has promising market potential [4]. Section 4: Financial Forecast & Investment Recommendations - The revenue forecast for 2025-2027 is adjusted to 2.08 billion, 2.48 billion, and 2.99 billion yuan, with net profits of 212.53 million, 288.09 million, and 395.93 million yuan respectively [5]. - The company is expected to see significant growth in the plant extraction and synthetic biology sectors, maintaining a "Buy" rating [5].